Drug Discovery and Development of miRNA-Based Nucleotide Drugs for Gastrointestinal Cancer.
Hiromichi SatoTomoaki HaraSikun MengYoshiko TsujiYasuko AraoKazuki SasakiNorikatsu MiyoshiShogo KobayashiYuichiro DokiHidetoshi EguchiHideshi IshiiPublished in: Biomedicines (2023)
Short non-coding RNAs, miRNAs, play roles in the control of cell growth and differentiation in cancer. Reportedly, the introduction of miRNAs could reduce the biologically malignant behavior of cancer cells, suggesting a possible use as therapeutic reagents. Given that the forced expression of several miRNAs, including miR-302, results in the cellular reprograming of human and mouse cells, which is similar to the effects of the transcription factors Oct4, Sox2, Klf4, and c-Myc, this suggests that the selective introduction of several miRNAs will be able to achieve anti-cancer effects at the epigenetic and metabolic levels. In this review article, we bring together the recent advances made in studies of microRNA-based therapeutic approaches to therapy-resistant cancers, especially in gastrointestinal organs.
Keyphrases
- transcription factor
- drug discovery
- papillary thyroid
- squamous cell
- cell proliferation
- induced apoptosis
- endothelial cells
- poor prognosis
- long non coding rna
- stem cells
- dna methylation
- lymph node metastasis
- childhood cancer
- optical coherence tomography
- long noncoding rna
- endoplasmic reticulum stress
- dna binding
- bone marrow
- mesenchymal stem cells
- young adults
- cell therapy
- drug induced
- optic nerve